KYMR · NASDAQ
Kymera Therapeutics (KYMR) Stock Price & Fundamentals
Kymera Therapeutics (KYMR) closed at $634.08 on Oct 9, 2026, up 0.06% from the previous close of $633.73.
Share price, past year
1Y +1.80%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $634.08 |
| Sep 30, 2026 | $622.06 |
| Aug 31, 2026 | $582.29 |
| Jul 31, 2026 | $590.75 |
| Jun 30, 2026 | $607.64 |
| May 29, 2026 | $604.25 |
| Apr 30, 2026 | $621.60 |
| Mar 31, 2026 | $646.59 |
| Feb 27, 2026 | $660.92 |
| Jan 30, 2026 | $672.77 |
| Dec 31, 2025 | $664.28 |
| Nov 28, 2025 | $662.52 |
| Oct 31, 2025 | $617.99 |
Key statistics
- Market cap
- $52.49B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.25
- Revenue (TTM)
- $105.00M
- Net income (TTM)
- −$299.60M
- Shares outstanding
- 82.8M
- Dividend yield
- —
- 52-week range
- $571.53 – $685.99
Kymera Therapeutics's market cap is $52.49B, based on a share price of $634.08 and 82.8M shares outstanding as of Jun 30, 2026.
Financials
Kymera Therapeutics reported revenue of $39.21M for fiscal 2025, down 16.70% from fiscal 2024.
Kymera Therapeutics reported a net loss of $311.35M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $39.21M | −16.7% | −$311.35M | −794.0% | −$3.69 | −$234.34M |
| FY2024ended Dec 31, 2024 | $47.07M | −40.1% | −$223.86M | −475.6% | −$2.98 | −$207.34M |
| FY2023ended Dec 31, 2023 | $78.59M | +67.8% | −$146.96M | −187.0% | −$2.52 | −$137.31M |
| FY2022ended Dec 31, 2022 | $46.83M | −35.7% | −$154.81M | −330.6% | −$2.87 | −$155.92M |
| FY2021ended Dec 31, 2021 | $72.83M | +114.0% | −$100.22M | −137.6% | −$2.09 | −$130.54M |
| FY2020ended Dec 31, 2020 | $34.03M | +1,060.0% | −$45.59M | −134.0% | −$3.15 | $79.03M |
| FY2019ended Dec 31, 2019 | $2.93M | — | −$41.25M | −1,405.8% | −$24.28 | $17.37M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $65.00M | −$61.21M | −$0.62 |
| Q1 FY2026ended Mar 31, 2026 | $34.37M | −$69.23M | −$0.71 |
| Q4 FY2025ended Dec 31, 2025 | $2.87M | −$86.98M | −$0.98 |
| Q3 FY2025ended Sep 30, 2025 | $2.76M | −$82.18M | −$0.94 |
| Q2 FY2025ended Jun 30, 2025 | $11.48M | −$76.61M | −$0.95 |
| Q1 FY2025ended Mar 31, 2025 | $22.10M | −$65.58M | −$0.82 |
| Q4 FY2024ended Dec 31, 2024 | $7.39M | −$70.75M | −$0.89 |
| Q3 FY2024ended Sep 30, 2024 | $3.74M | −$62.49M | −$0.82 |
Company profile
- Name
- Kymera Therapeutics, Inc.
- Ticker
- KYMR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 500 North Beacon Street, 4th Floor, Watertown, MA 02472
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001815442
Recent SEC filings
- Aug 5, 2026
- Aug 5, 2026
- Jul 27, 2026
- Jun 25, 2026
- Jun 24, 2026
- Jun 8, 2026
- Apr 30, 2026
- Apr 30, 2026
Frequently asked questions
What is Kymera Therapeutics's stock price?
Kymera Therapeutics (KYMR) closed at $634.08 on Oct 9, 2026, up 0.06% from the previous close of $633.73.
What is Kymera Therapeutics's market cap?
Kymera Therapeutics's market cap is $52.49B, based on a share price of $634.08 and 82.8M shares outstanding as of Jun 30, 2026.
How much revenue does Kymera Therapeutics make?
Kymera Therapeutics reported revenue of $39.21M for fiscal 2025, down 16.70% from fiscal 2024.
Does Kymera Therapeutics pay a dividend?
Kymera Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Kymera Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures